Meeting
2023 ASCO Annual Meeting
Detection of ctDNA in patients with stage III cutaneous melanoma with satellite/in-transit or nodal metastases.
Authors
Jafar Al-Mondhiry
Inova Schar Cancer Institute, Fairfax, VA
Jafar Al-Mondhiry , Chelsea Stahl , Suraj S. Venna , Sekwon Jang
Organizations
Inova Schar Cancer Institute, Fairfax, VA
Research Funding
No funding received
None.
Background: Circulating tumor DNA (ctDNA) has emerged as a biomarker to monitor disease status in cancer patients. Limited data exists on the sensitivity of ctDNA for detection of satellite/in-transit or nodal metastases in melanoma. Methods: We conducted a retrospective study of stage III cutaneous melanomas with clinically detected satellite/in-transit and/or lymph node metastases who underwent ctDNA analysis using an mPCR-NGS-based ctDNA assay ("Signatera") prior to surgery or systemic therapy at Inova Schar Cancer Institute. Results: ctDNA was detected in 4 of 14 patients including 1 of 3 patients with both satellite/in-transit metastases and nodal metastases; 3 of 6 patients with nodal metastases only; none of 5 patients with satellite/in-transit metastases only. Nodal tumor burden (sum of short axis of involved lymph nodes) for ctDNA detected patients was greater than 1.5cm (5.0cm, 3.0cm, 3.0cm, and 1.6cm, respectively), and 1.5cm or less in patients whose ctDNA were not detected. Conclusions: ctDNA may not detect satellite/in-transit metastases or small nodal metastases in melanoma. A larger study is needed to validate this finding.
| Age | Sex | T stage | N stage | Nodal metastases (nodal burden) | Satellite/in-transit metastases | Mutation detected | ctDNA detected |
|---|---|---|---|---|---|---|---|
| 71 | F | T1a | N2c | Yes (1.5cm) | Yes | NRAS | not detected |
| 59 | M | T2b | N1c | No | Yes | NRAS | not detected |
| 45 | M | T2b | N3c | Yes (1.1cm) | Yes | BRAF | not detected |
| 80 | F | T3b | N1c | No | Yes | NRAS | not detected |
| 51 | M | T2a | N2c | No | Yes | BRAF | not detected |
| 78 | M | T4b | N3b | Yes (1.0cm) | No | ARID | not detected |
| 78 | M | T1b | N1c | No | Yes | NA* | not detected |
| 55 | M | T3a | N1b | Yes (1.3cm) | No | NF1 | not detected |
| 64 | F | Tx | N1a | Yes (0.7cm) | No | BRAF | not detected |
| 68 | M | T3a | N2c | No | Yes | NRAS | not detected |
| 83 | F | Tx | N3b | Yes (3.0cm) | No | BRAF | detected (0.05 MTM/mL) |
| 67 | M | T3a | N2b | Yes (1.6cm) | No | NF1 | detected (0.66 MTM/mL) |
| 29 | M | T4b | N1b | Yes (5.0cm) | No | NRAS | detected (0.15 MTM/mL) |
| 48 | F | T4b | N3c | Yes (3.0cm) | Yes | BRAF | detected (7.88 MTM/mL) |
*NA: Not available.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Publication Only
Session Title
Publication Only: Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr e21559)
DOI
10.1200/JCO.2023.41.16_suppl.e21559
Abstract #
e21559
Abstract Disclosures
Similar Abstracts
Abstract
2024 ASCO Breakthrough
Early circulating tumor DNA (ctDNA) changes during treatment with immune checkpoint inhibitors (ICI) as a predictor of clinical outcomes in patients (pts) with advanced stage melanoma/skin cancer.
First Author: Vincent T. Ma
Abstract
2023 ASCO Annual Meeting
Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with surgically resected stage II/III melanoma.
First Author: Revathi Kollipara
Abstract
2023 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) to assess response in patients with anal cancer treated with definitive chemoradiation.
First Author: Janet Alvarez
Abstract
2024 ASCO Gastrointestinal Cancers Symposium
Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.
First Author: Pashtoon Murtaza Kasi